Xiamen University researchers report that lithocholic acid extended mouse lifespan by 5%, though human anti-aging benefits remain unproven in clinical trials.
On October 1 2026, CGTN reported that a Xiamen University team studied lithocholic acid in the context of aging and calorie restriction. This research was led by Chinese Academy of Sciences academician Lin Shengcai.
According to the CGTN account of the team's findings, lithocholic acid helped repair muscle damage and improved stamina in older mice. Longevity tests conducted by the researchers indicated an approximately 5% lifespan extension. These preclinical outcomes position the gut-microbe-derived molecule as a potential biological mediator of calorie restriction. However, the available reporting does not establish any corresponding anti-aging benefit in humans.
This research was conducted entirely in animal models rather than in human subjects.
The search for compounds that influence the biology of aging often leads researchers to investigate the digestive system and its complex metabolic outputs. Lithocholic acid is classified as a secondary bile acid, which means it is heavily modified by the microbiome before it enters circulation. This classification as a gut-microbe product highlights the intricate relationship between digestive health and systemic aging. In recent years, emerging longevity science has increasingly focused on how these gut-derived metabolites interact with cellular longevity pathways.
While gut-derived metabolites fit neatly into emerging aging hypotheses, their precise mechanisms remain challenging to isolate. The Xiamen University study aimed to understand how this specific bile acid operates during periods of metabolic stress. Because bile acids facilitate nutrient absorption and metabolic signaling, they are uniquely positioned to influence how the body allocates energy. However, observing a biological interaction in a controlled laboratory setting is vastly different from proving a systemic health benefit.
To fully grasp the implications of the Xiamen University findings, it is necessary to understand the role of calorie restriction in longevity science. Reducing caloric intake without causing malnutrition is one of the most consistently studied interventions for extending lifespan in animal models. The 2025 Nature paper cited in subsequent literature notes that lithocholic acid phenocopies the anti-aging effects of calorie restriction. This means the molecule appears to trigger similar biological responses to those caused by actual dietary scarcity.
In the Xiamen University experiments, mice were given just 70% of their normal food intake. Following a period of hunger, researchers observed that blood levels of lithocholic acid rose more than tenfold. This significant metabolic response illustrates how tightly nutrient sensing is coupled to gut-microbe products in mice. However, relying on extreme dietary deprivation to trigger these pathways presents a significant practical challenge.
Restricting an animal to 70% of its normal caloric intake is a severe intervention that is difficult for human populations to sustain. Therefore, researchers often search for specialized compounds that can activate these cellular longevity pathways without requiring literal starvation. The observed tenfold rise in lithocholic acid suggests it acts as an internal biological signal mimicking food scarcity. Despite this fascinating mechanism, taking external supplements to artificially replicate these physiological effects remains unproven.
The research team observed multiple physiological changes in the older mice following the intervention. According to the CGTN report, the administration of lithocholic acid helped repair accumulated muscle damage. The treated animals also demonstrated improved physical stamina when compared to the control group. These findings align with earlier preclinical research spanning age-related muscle measures and metabolic outcomes in animal models.
A summary provided in a later Life Metabolism paper offers additional cellular context for these physical improvements. The paper describes prior aged-mouse findings that include increased NAD+ levels following lithocholic acid administration. These cellular changes translated into better grip strength and longer running performance. The doses used in these earlier experiments produced circulating levels comparable to those observed after actual calorie restriction.
Evaluating whether these cellular changes actually reflect improved tissue resilience requires closely examining the specific animal models involved. The ability of a secondary bile acid to influence NAD+ levels suggests a deep connection between gut metabolism and cellular energy production. However, improving grip strength in an aged mouse does not automatically translate to preventing physical decline in human populations. Scientists must carefully map these biological pathways to ensure they operate similarly in far more complex human systems.
The biological mechanisms observed in these studies operate within the highly controlled environment of a laboratory. The Life Metabolism article notes that organism-level lifespan and healthspan benefits have also been tested in the nematode C. elegans and the fruit fly Drosophila melanogaster. While these model organisms are essential for early biological research, their physiology differs vastly from human biology. Isolated laboratory biology rarely translates directly into effective human therapies without extensive clinical modification.
The evolutionary distance between these simple organisms and human beings is vast. While a nematode worm can demonstrate organism-level lifespan benefits from a specific intervention, its biological architecture lacks mammalian complexity. Fruit flies provide excellent data on basic genetic pathways, but they do not possess the nuanced metabolic networks found in human patients. Therefore, results from these preliminary testing phases must always be interpreted with strict caution.
The most prominent claim from the Xiamen University study is the reported increase in absolute longevity. CGTN reports that the team observed an approximately 5% lifespan extension during their mouse longevity tests. While a 5% increase is biologically notable in a laboratory setting, evaluating the true strength of this finding requires statistical context. Unfortunately, the available reporting does not supply enough design or statistical detail to independently evaluate the result.
Crucial data points are currently missing from the public narrative surrounding this research. The available source does not provide the sample size of the longevity tests or the absolute lifespan values of the mice. Without these specific statistical details, it is difficult to determine the precise significance of the 5% figure. As a result, this lifespan finding should be treated as an early-stage research signal rather than a definitive scientific conclusion.
The investigation into lithocholic acid extends beyond mice, though the endpoints of these other studies differ significantly. A separate 2026 Life Metabolism paper investigated the effects of the molecule on fatty liver disease. This research involved both mice and non-human-primate macaques. The abstract-level summary states that the treatment successfully alleviated fatty liver in both animal models.
It is vital to separate these targeted metabolic findings from generalized lifespan claims. Alleviating fatty liver in macaques is a distinct clinical outcome related to specific metabolic dysfunction. It is not a primate lifespan test, and it should not be presented as evidence that the molecule extends primate life. Treating a specific liver condition in an animal model does not equate to proving a human longevity benefit.
Stanford structural-biology professor Michael Levitt provided important context on this translational gap in the same CGTN story. He emphasized that human healthspan is incredibly complex and cannot be reduced to a single molecular intervention. Instead, he described healthspan as being shaped heavily by social and behavioral factors. This perspective serves as a necessary counterweight to the enthusiasm often surrounding isolated preclinical findings.
Levitt specifically highlighted the importance of foundational lifestyle habits over speculative biological interventions. He noted that factors like diet, exercise, and not smoking play critical roles in maintaining long-term health. Furthermore, he emphasized the value of spending time in nature and maintaining friendships. These holistic behavioral variables often exert a far greater influence on human aging than early-stage metabolic compounds.
Translating the findings from the Xiamen University study into practical human applications requires a high degree of caution. The available sources do not establish a clinical trial showing that lithocholic acid extends human lifespan or improves human healthspan. There is currently no evidence proving that the molecule is safe and effective as an anti-aging treatment. Without comprehensive human trials, utilizing these findings to inform personal health decisions remains entirely speculative.
Readers should treat these results as early-stage research findings rather than immediate medical guidance. The tenfold rise in the molecule only occurred under severe dietary restriction, which is difficult and potentially dangerous for humans to replicate. The sources cited here provide no human anti-aging dosing guidance or clinical outcome evidence. Therefore, this research should not be used as a reason to attempt severe calorie restriction or to pursue unproven dietary supplements.
Future clinical validation must move beyond basic animal models to determine if lithocholic acid safely influences measurable biomarkers of aging in human trials.
Navigating overstated claims around biological age, supplements, peptides and emerging therapies requires separating preliminary animal biology from human clinical reality. AgeAmaze addresses the difficulty distinguishing animal research from human evidence, providing research-minded adults with well-sourced explanations of biological mechanisms so they understand what is established and what remains speculative. Read the research
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
